SCHEMBL6785154

SCHEMBL6785154

C/C(=C/C(=O)Nc1ccccc1C(=O)O)c1ccc2cc(C)ccc2c1

nearest known ligand 0.84

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.84
DHODH Q02127 1/20 0.50
KDM4E B2RXH2 2/20 0.48
LMNA P02545 1/20 0.45
LTB4R Q15722 1/20 0.45
ALDH1A1 P00352 1/20 0.45
POLB P06746 1/20 0.45
DEGS1 O15121 1/20 0.43
AKR1B10 O60218 1/20 0.43
AKR1B1 P15121 1/20 0.43
AKR1C4 P17516 1/20 0.43
AKR1C3 P42330 1/20 0.43
AKR1C2 P52895 1/20 0.43
AKR1C1 Q04828 1/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
TRPA1 O75762 1/20 0.43
MAPT P10636 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4022937 0.91 TERT (1.00) TERTDHODHKDM4ELTB4RALDH1A1
SCHEMBL30760782 0.91 TERT (1.00) TERTDHODHKDM4ELTB4RALDH1A1
SCHEMBL29362821 0.91 TERT (1.00) TERTDHODHKDM4ELTB4RALDH1A1
SCHEMBL16964998 0.91 TERT (1.00) TERTDHODHKDM4ELTB4RALDH1A1
SCHEMBL29355750 0.91 TERT (1.00) TERTDHODHKDM4ELTB4RALDH1A1
SCHEMBL29966843 0.91 TERT (1.00) TERTDHODHKDM4ELTB4RALDH1A1
SCHEMBL6785228 0.89 TERT (0.78) TERTKDM4ELTB4RNPC1RAB9A
SCHEMBL6786444 0.89 TERT (0.78) TERTDHODHKDM4ELTB4RALDH1A1
SCHEMBL22796557 0.86 TERT (0.80) TERTDHODHKDM4ELTB4RALDH1A1
SCHEMBL6788013 0.85 TERT (0.62) TERTDHODHALDH1A1AKR1C3AKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
EP-1261321-A2 CARBOXYLIC ACID AMIDES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND THE USE AND PRODUCTION THEREOF Boehringer Ingelheim Pharma KG (DE) 2002-12-04 EP disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed
WO-2001007020-A2 CARBOXYLIC ACID AMIDES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND THE USE AND PRODUCTION THEREOF BOEHRINGER INGELHEIM PHARMA KG (DE) 2001-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885DHODH 1011/4885KDM4E 1243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.